“The benefit of new drugs, evaluated in the short term, is too uncertain”
NOTe doctors, pharmacists, statisticians, researchers, scientists, involved in the care and clinical trials evaluating new drugs for people with cancer, are concerned about the emergence of a discourse questioning the scientific knowledge on which based on the medical assessment. In particular, it appears that the most effective method for assessing the efficacy of therapeutic innovations,…